# CURRENT CLINICAL TRIALS

Mercer University Clinical Research Department is proud to offer a large number of clinical trials for patients and potential patients. Our researchers start new trials throughout the year, so the list is updated frequently. For questions regarding a specific clinical trial, please contact the Clinical Research Manager at 478-301-5846, and she will direct you to the appropriate study coordinator.

## ENROLLING STUDIES:

- **EYEWITNESS (219516):** A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed.

- **MK-8591A-052:** A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants with HIV 1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF).

- **MK-8591A-053:** A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants

## STUDIES IN FOLLOW UP:

- **GS-US-200-4334:** A phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-Acting Capsid Inhibitor (GS 6207 in Combination with Other Antiretroviral Agents in Patients Living with HIV

- **GS-US-621-6289:** An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens

- **GSK-FLAIR (201584)**: A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naïve Adult Participants

- **MK-8591A-018:** A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/ Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

- **MK-8591A-054:** A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study

- **JANSSEN – DEFINE:** A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fix-dose Combination (FDC) Regimen in the Virologically suppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain in an INI + TAF/FTC ARV Regimen

MERCER UNIVERSITY
SCHOOL OF MEDICINE
*Clinical Research*